Cost-Effectiveness of PD-L1 Testing in Non-Small Cell Lung Cancer (NSCLC) Using In Vitro Diagnostic (IVD) Versus Laboratory-Developed Test (LDT)

INTRODUCTION: Accurate PD-L1 testing for non-small cell lung cancer (NSCLC) maximizes the benefits of immune checkpoint inhibitor (ICI) drugs like pembrolizumab. False negative test results deny ICI treatments to eligible patients, worsening clinical and economic outcomes, while false positives incr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hurwitz, Jason T., Vaffis, Shannon, Grizzle, Amy J., Nielsen, Søren, Dodson, Andrew, Parry, Suzanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681966/
https://www.ncbi.nlm.nih.gov/pubmed/35556235
http://dx.doi.org/10.1007/s40487-022-00197-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681966/
https://www.ncbi.nlm.nih.gov/pubmed/35556235
http://dx.doi.org/10.1007/s40487-022-00197-1

Ejemplares similares